Chest
Original ResearchDiffuse Lung DiseaseRecombinant Human Thrombomodulin in Acute Exacerbation of Idiopathic Pulmonary Fibrosis
Section snippets
Baseline Characteristics
A patient flow diagram is shown in Figure 1. In the study period, 44 consecutive patients were admitted for AE-IPF. Four of these patients were excluded, including two with previous episodes of AE, one with complication of severe acute cholecystitis, and one who refused further medical treatment. The remaining 40 patients met the inclusion criteria. They included 36 men and four women, with a median age of 72 years (range, 43-90 years) (interquartile range, 66-78 years). Median Pao2/Fio2 at
Discussion
This is the first study, to our knowledge, to investigate the efficacy of rhTM for AE-IPF. We showed that rhTM was associated with a better outcome for 3-month mortality (30%). Using a logistic regression model, it was also shown to improve 3-month survival. Administration of rhTM appeared to be safe without any major adverse effects.
We found high levels of D-dimer in BALF in patients with AE-IPF, which reflect a disturbance in intraalveolaractivated coagulation. We also showed an elevated
Acknowledgments
Author contributions: K. K. served as principal author, had access to and takes responsibility for the integrity of the data and the accuracy of the data analysis. Y. K., O. N., and K. S. contributed to the study concept and design; T. K., T. M., and T. Y. contributed to data collection; H. T., T. K., T. M., T. Y., and M. A. contributed to data analysis; T. K., T. M., and T. Y. contributed to preparation and review of the manuscript; Y. K., O. N., K. S., and M. A. contributed to the writing and
References (28)
- et al.
Anticoagulant therapy for idiopathic pulmonary fibrosis
Chest
(2005) - et al.
Biologic markers of mortality in acute lung injury
Clin Chim Acta
(2006) - et al.
Acute exacerbation in idiopathic pulmonary fibrosis. Analysis of clinical and pathologic findings in three cases
Chest
(1993) - et al.
Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial
J Thromb Haemost
(2007) - et al.
Lectin-like domain of thrombomodulin binds to its specific ligand Lewis Y antigen and neutralizes lipopolysaccharideinduced inflammatory response
Blood
(2008) - et al.
The lectin-like domain of thrombomodulin interferes with complement activation and protects against arthritis
J Thromb Haemost
(2006) - et al.
Thrombomodulin: protectorate God of the vasculature in thrombosis and inflammation
J Thromb Haemost
(2011) - et al.
Clinical course and prediction of survival in idiopathic pulmonary fibrosis
Am J Respir Crit Care Med
(2011) - et al.
Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis
Am J Physiol Lung Cell Mol Physiol
(2010) - et al.
Enhanced tissue factor pathway activity and fibrin turnover in the alveolar compartment of patients with interstitial lung disease
Thromb Haemost
(2000)
Mechanisms of fibroproliferation in acute lung injury
The clinical course of patients with idiopathic pulmonary fibrosis
Ann Intern Med
Elevated levels of plasminogen activator inhibitor-1 in pulmonary edema fluid are associated with mortality in acute lung injury
Am J Physiol Lung Cell Mol Physiol
Protein C and thrombomodulin in human acute lung injury
Am J Physiol Lung Cell Mol Physiol
Cited by (89)
Prognostic value of the qSOFA in patients with acute exacerbation of idiopathic pulmonary fibrosis
2023, Respiratory InvestigationCharacteristics and evaluation of acute exacerbations in chronic interstitial lung diseases
2021, Respiratory MedicineAcute Exacerbation of Idiopathic Pulmonary Fibrosis
2021, Encyclopedia of Respiratory Medicine, Second Edition
originally published Online First March 26, 2015.
FUNDING/SUPPORT: This study was partially supported by a grant to the Diffuse Lung Disease Research Group from the Ministry of Health, Labor and Welfare, Japan, and the NPO Respiratory Disease Conference.
Reproduction of this article is prohibited without written permission from the American College of Chest Physicians. See online for more details.